RFK Jr. Pushes Alzheimer's Screening While USPSTF Remains Paralyzed for Over a Year
核心洞察
The U.S. Preventive Services Task Force (搜索) has been blocked from meeting since March 2025, stalling new guidance on cognitive decline screening despite the health secretary's calls for action.
Health Secretary Robert F. Kennedy Jr. has called the lack of early Alzheimer's screening "regulatory malpractice," yet his department dismissed the task force's leadership and failed to fill vacancies.
An estimated 7.4 million Americans aged 65 and older live with Alzheimer's disease (搜索), and researchers say science has been "slowed down" by funding disruptions affecting 14 of 35 Alzheimer's Disease Research Centers.
The U.S. Preventive Services Task Force (搜索) (USPSTF), the nation's leading independent panel of experts on preventive care, has been unable to convene since March 2025, leaving critical guidance on cognitive decline screening in limbo even as Health Secretary Robert F. Kennedy Jr. publicly demands better Alzheimer's detection.
The task force, which typically meets three times a year, was poised to issue new recommendations on screening for cognitive decline this year alongside 13 other topics including autism screening and food allergy prevention. It is not scheduled to meet again until late August, bringing its hiatus to roughly 17 months.
"It's almost regulatory malpractice that we do not have early screening already," Kennedy told the House energy and commerce subcommittee in April, while also criticizing the USPSTF as "lackadaisical and negligent for 20 years" during separate congressional testimony.
Yet at the time of those remarks, the health department had already prevented the panel from meeting for more than a year and failed to fill at least eight vacancies on the 16-member body. In May, Dr. Roger Klein, director of the Agency for Healthcare Research and Quality and a political appointee, dismissed two task force chairs. The panel could convene in August with as many as eight new members, according to Axios.
Scientific uncertainty around widespread screening
The push for broader Alzheimer's screening comes amid significant scientific debate over whether the evidence supports routine testing. John Ruiz, a professor of clinical psychology at the University of Arizona and a recent task force member who rotated off in January, described the evidence base as fragmented.
"The evidence for cognitive screening for dementia is not great," Ruiz said. "You get 10 neurologists, you get 10 approaches on how they're going to assess that – there's no consensus. The evidence is mixed at best."
The task force's approach, Ruiz explained, has been to call for more funding to build the evidence base and allow researchers to conduct screening studies. USPSTF draft recommendations are open for public comment and frequently receive substantial input from research communities, helping to shape future investigation.
Some researchers believe Kennedy may be referring to new blood biomarker tests for P-Tau217 (搜索), a diagnostic tool approved in May 2025. The test is cleared for people older than 50 experiencing signs and symptoms of Alzheimer's — not for broad screening. The Alzheimer's Association has promoted such blood tests as a "mammogram moment," but experts have urged caution.
"I disagree with [Kennedy's] assertion we should be rolling those out broadly," said Ann D. Cohen, co-director of the University of Pittsburgh Alzheimer's Disease (搜索) Research Center and associate professor of psychiatry. "They have very good diagnostic – not prognostic – value." Cohen noted that one study suggested the tests could be subject to many false-positive results in real-world settings.
Research funding disruptions
Cohen's own work advancing screening tools was directly impacted by Trump administration policies. The Guardian reported in March 2025 that 14 of the nation's 35 Alzheimer's Disease (搜索) Research Centers faced funding freezes, making it difficult to retain staff and clinical trial patients.
Cohen's funding did not clear until the "end of last summer," forcing her to use "several hundred thousand dollars" in philanthropic funds originally earmarked to advance blood biomarker tests. "We had to cancel that because we had to use those funds to keep our clinic open," she said. "There's no way around the fact that science has been slowed down."
Concerns over task force independence
Health policy experts have warned that Kennedy could attempt to remake the independent task force in the same manner he overhauled the Advisory Committee on Immunization Practices, where he fired all 17 members citing conflicts of interest and replaced them with vaccine skeptics.
"There's the potential that they could reform [the USPSTF] in a way that is no longer evidence-based or scientific," Aaron Carroll, president and CEO of AcademyHealth, told Politico. "In which case they can force insurance to cover things with no out-of-pocket costs, but things that might not be evidence-based or potentially could cause more harm than good."
The USPSTF's A-to-D ratings carry direct financial implications for Americans, as they determine which preventive health screenings insurers must cover at no cost under federal law.
Disease burden and the case for early detection
An estimated 7.4 million Americans aged 65 and older live with Alzheimer's disease (搜索), the most common form of dementia. About 200,000 Americans in middle age are also diagnosed, according to the Alzheimer's Association. Although older people account for the vast majority of cases, Alzheimer's is not considered a normal part of aging.
Currently, Alzheimer's screening typically relies on the appearance of symptoms, followed by cognitive testing such as word recall, referral to a neurologist, and potentially imaging such as MRI. There is no major treatment for Alzheimer's, making the search for reliable screening urgent, since early detection could lead people to undertake healthy lifestyle changes to delay cognitive decline.
"There's not like where you might go get a mammogram for breast cancer screening – there's nothing like that set up for Alzheimer's disease (搜索) or cognitive impairment," said Allison Aiello, a professor of health longevity and epidemiology at Columbia University, whose population studies are seeking biomarkers and cognitive tests that could detect changes as early as ages 24 to 44.
Aiello also drew a distinction between developing tests and deploying them broadly. "If we can measure these kinds of things we know are associated with cognitive impairment and Alzheimer's in older age, we might be able to find small nuanced changes that characterize patterns that lead to change in older life," she said. "Should we be doing that at every primary care visit? That's a whole other question."
An HHS spokesperson told The Guardian that the department "remains committed to advancing research in Alzheimer's disease (搜索) and other serious health conditions," noting that NIH remains the federal government's largest funder of Alzheimer's research, CMS is expanding access to coordinated dementia care through the nationwide Guide model, and FDA continues to oversee new Alzheimer's therapies and diagnostics.
Following Kennedy's remarks on Alzheimer's in May 2025, the Alzheimer's Impact Movement accused him of spreading misinformation about the disease, saying he "owes an apology" to those living with Alzheimer's and their families, and urged him to "stop spreading these harmful Alzheimer's myths, and preserve the nation's investment in Alzheimer's research."